Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort

Anwaar Saeed (), Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Weijing Sun, Stephen Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Abushukair, Kelly Mulvaney, Andrew K. Godwin and Azhar Saeed
Additional contact information
Anwaar Saeed: University of Pittsburgh Medical Center (UPMC)
Robin Park: Moffitt Cancer Cente
Harsh Pathak: University of Kansas Medical Center
Ayah Nedal Al-Bzour: University of Pittsburgh Medical Center (UPMC)
Junqiang Dai: University of Kansas Medical Center
Milind Phadnis: University of Kansas Medical Center
Raed Al-Rajabi: University of Kansas Medical Center
Anup Kasi: University of Kansas Medical Center
Joaquina Baranda: University of Kansas Medical Center
Weijing Sun: University of Kansas Medical Center
Stephen Williamson: University of Kansas Medical Center
Yu-Chiao Chiu: UPMC Hillman Cancer Center
Hatice Ulku Osmanbeyoglu: UPMC Hillman Cancer Center
Rashna Madan: University of Kansas Medical Center
Hassan Abushukair: University of Pittsburgh Medical Center (UPMC)
Kelly Mulvaney: University of Kansas Cancer Center
Andrew K. Godwin: University of Kansas Medical Center
Azhar Saeed: University of Vermont Medical Center

Nature Communications, 2024, vol. 15, issue 1, 1-13

Abstract: Abstract CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS tumors. Primary endpoint was met with ORR of 27.6% (95% CI 12.7-47.2%). Secondary endpoints of 4-month PFS rate was 44.83% (95% CI 26.5-64.3%); and median OS was 9.1 months (95% CI 5.8-20.2). Grade≥3 TRAE occurred in 39%. In post-hoc analysis of patients with RAS wild type tumors, ORR was 50% and median PFS and OS were 6.3 and 21.5 months respectively. Exploratory spatial transcriptomic profiling of pretreatment tumors showed upregulation of VEGF and MET signaling, increased extracellular matrix activity and preexisting anti-tumor immune responses coexisting with immune suppressive features like T cell migration barriers in responders versus non-responders. Cabozantinib plus durvalumab demonstrated anti-tumor activity, manageable toxicity, and have led to the activation of the phase III STELLAR-303 trial.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-45960-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45960-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-45960-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().